During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, MyelomaSeptember 27, 2024
EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantAccess, MyelomaSeptember 26, 2024
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, latest, Myeloma, NewsJuly 17, 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, latest, MyelomaJuly 9, 2024
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”AL amyloidosis, MPEApril 24, 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
